Thermo Fisher Scientific Inc. $TMO Shares Sold by Dakota Wealth Management

Key Points

• Dakota Wealth Management reduced its stake in Thermo Fisher Scientific by 14.2%, now holding 5,050 shares valued at approximately $2.05 million after selling 839 shares in the second quarter.
• Several institutional investors significantly increased their positions in Thermo Fisher, with GAMMA Investing LLC boosting its stake by 60,610.9% to over $1.2 billion in value.
• The company declared a quarterly dividend of $0.43 per share, representing an annualized payout of $1.72 and a dividend yield of 0.4%.

Dakota Wealth Management lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,050 shares of the medical research company's stock after selling 839 shares during the quarter. Dakota Wealth Management's holdings in Thermo Fisher Scientific were worth $2,048,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TMO. GAMMA Investing LLC boosted its position in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. Nuveen LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at approximately $532,360,000. Sarasin & Partners LLP acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at approximately $242,991,000. EdgePoint Investment Group Inc. acquired a new position in Thermo Fisher Scientific during the 1st quarter worth $172,139,000. Finally, Cohen Investment Advisors LLC boosted its position in Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock worth $167,271,000 after acquiring an additional 331,180 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Evercore ISI reduced their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Finally, Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. Sixteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $588.35.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $464.18 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $175.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 2.49 and a beta of 0.75. The stock has a fifty day moving average of $476.70 and a 200-day moving average of $448.02. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.